Table 1

Characteristics of patients harboring TP53 mutations

Patient no.Clinical responseTypeMutationp53 IHCaLOHbIHCHistological gradeOSeRFSf
CodonNucleotid changeAffecting L2/L3 domainc-erbB-2cbcl-2d
11PDStop204GAG-TAGYes1NDg23215.50
19PDTransition249AGG-GGGYes1Yes003200
26PDDeletion217–22114 bpYes0Yes33242.79.4h
57PDTransition248CGG-CAGYes9ND3339.50
95PDSplice/deletion i G-AYes9Yes12333.10
5StbDSplice/deletion i G-AYes9Yes00317.69.1
22StbDTransition266GGA-AGANo9Yes33333.69.7
37StbDTransversion176TGC-TTCYes9Yes0032212.1
51StbDDeletion232–2346 bpYes6Yes06360.360.3j
55StbDTransition190CCT-CTTYes0No20216.510.5
63StbDTransition286GAA-AAANo6Yes13341.224.7
64StbDTransition273CGT-CATNo4No26256.456.4j
80StbDTransition175CGC-CACYes6Yes30211.38.7
92kStbDTransversion168CAC-CCCYes9Yes20329.40
98StbDTransition277TGT-TATNo6Yes03231.931.9j
1PRTransition151CCC-TCCNo6Yes09324.115.8
7PRTransition273CGT-CATNo6No0628939.4
15PRTransition163TAC-TGCYes9Yes03379.179.1j
20kPRSplice/deletion i G-AYes0ND06118.60
39PRTransversion237ATG-ATTYes6Yes03266.866.8j
41kPRTransition273CGT-CATNo9Yes0038.60
53PRDeletion239–24211 bpYes1No32234.122.9
75kPRTransversion244GGC-AGCYes4ND23140.20
100PRStop165CAG-TAGYes0Yes09316.910.1
101PRStop136CAA-TAAYes0Yes32232.919.9j
109PRStop213CGA-TGAYes0Homozygote02325.525.5j
  • a p53 immunohistochemistry given as staining index (product of staining intensity and area).

  • b LOH at the TP53 locus.

  • c Membraneous c-erbB-2 immunostaining given as staining intensity; 0, negative; 1, weak; 2, moderate; and 3, strong.

  • d bcl-2 immunostaining given as staining index.

  • e Breast cancer-specific survival.

  • f Recurrence-free survival (both given in months).

  • g ND, not determined because of lack of tissue.

  • h Patient 26 received palliative surgery after 12 weeks on first-line chemotherapy.

  • i Mutation located 1 bp upstream of exon 5, causing a 21-bp deletion of exon 5 on cDNA.

  • j Patients still alive and relapse free at the end of the observation period.

  • k Primary stage IV (limited distant metastasis).